Loading people...
Karolina Zapadka is a Senior Investment Manager at Parkwalk Advisors, operating out of Cambridge and London in the United Kingdom. She holds a PhD in chemistry from the University of Cambridge and an Executive MBA from HEC Paris, transitioning from a scientific research background into venture capital. Prior to her current investment role, Zapadka spent over five years at MedImmune and served as the Chief Executive of KLZ Consulting starting in 2017, providing specialized biotechnology and healthcare consulting services. At Parkwalk Advisors, she targets pre-seed and seed investments across the life sciences, digital health, and pharmaceutical sectors, typically deploying initial check sizes between $1.3 million and $2 million. Leveraging nearly a decade of experience in company building, her current focus centers on identifying and supporting early-stage healthcare startups emerging from the Cambridge cluster.
Karolina Zapadka is a distinguished investor at Parkwalk Advisors, a leading venture capital firm renowned for its focus on university spin-out companies. In her role, Karolina is instrumental in sourcing, evaluating, and backing groundbreaking technologies and businesses that originate from the UK's world-class academic institutions. Her work directly contributes to Parkwalk's mission of bridging the gap between cutting-edge research and successful commercial ventures.
Parkwalk Advisors specializes in early-stage investments, particularly within the deep tech and life sciences sectors. Karolina's investment focus aligns perfectly with this strategy, seeking out companies that possess disruptive intellectual property and the potential for significant market impact. This includes areas such as artificial intelligence, advanced materials, biotechnology, clean energy, and quantum computing, among others. She is adept at assessing the scientific merit and commercial viability of complex technologies, working closely with founders to help them scale their innovations.
While specific details of Karolina Zapadka's individual career background are not extensively publicized, her position at Parkwalk Advisors suggests a strong foundation in finance, technology, or a related scientific discipline, coupled with a keen understanding of venture capital dynamics. Investors in this space often bring a blend of analytical rigor, strategic foresight, and a passion for fostering innovation. Her expertise is crucial in navigating the unique challenges and opportunities presented by university spin-outs, which often require patient capital and specialized support to transition from lab to market.
Parkwalk Advisors has a robust portfolio of successful investments, and Karolina's contributions are integral to the firm's continued growth and impact. While individual notable investments directly attributed to Karolina Zapadka are not typically highlighted publicly, her involvement ensures that promising ventures receive the necessary funding and strategic guidance to thrive. She is part of a team committed to nurturing the next generation of UK technology leaders, transforming academic breakthroughs into tangible economic and societal benefits.
For entrepreneurs and researchers seeking capital for their deep tech or life science spin-outs, understanding the investment thesis of professionals like Karolina Zapadka is key. Her dedication to supporting innovative companies underscores Parkwalk Advisors' commitment to driving technological advancement and economic growth across the UK.
Karolina Zapadka is an investor at Parkwalk Advisors, a leading venture capital firm specializing in university spin-out companies. She focuses on identifying and supporting early-stage deep tech and life science ventures.
Karolina Zapadka invests in early-stage companies, primarily university spin-outs, within the deep tech and life sciences sectors. Her focus includes areas like AI, advanced materials, biotechnology, and clean energy.
Karolina Zapadka works as an investor at Parkwalk Advisors, a prominent venture capital firm based in the UK that specializes in funding innovative companies emerging from university research.
